A día de hoy hay quince clinical trials (CT, ensayos clínicos) en el registro de ensayos clínicos promovido por la EMA ( EudraCT) sobre células CAR-T.
Por años de inicio se reparten: 1 en 2014; 2 en 2015, 4 en 2016, 5 en 2017 y van dos en 2018. Uno iniciado en 2017 no tienen fecha de inicio.
Por sponsor:
Autolus Limited promueve 3;
Bambino Gesú Children's Hospital promueve 1;
Celgene Corporation promueve 2;
IRCCS Ospedale Pediatrico Bambino Gesú promueve 1;
Kite Pharma, Inc. promueve 2;
Novartis Pharma AG promueve 1;
Novartis Pharma Services AG promueve 2;
University Hospital Heidelberg promueve 1;
University of Pennsylvania promueve 1
y Uppsala university promueve 1.
Por Medical condiction:
Acute lymphoblastic leukaemia (ALL)
Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
Adult patients > =18 years with relapsed or refractory DLBCL, having failed 2 or more lines of therapy and not eligible for HSCT B-cell
Acute Lymphoblastic Leukemia (ALL) CD19+
B cell lymphoma or leukemia Chemotherapy resistant or refractory
CD19+ B-cell Leukemia and Lymphoma.
Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B cell lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL).
High Risk and/or relapsed/refractory Neuroblastoma
Paediatric patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.
Patients who have been treated for a B cell hematological malignancy in a Novartis sponsored or supported study of CD19 directed CAR T-Cell treatment are enrolled in this study following completion..
Relapsed and Refractory Multiple Myeloma
Relapsed and/or refractory CD19+ leukemia and lymphoma
Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed or Refractory Multiple Myeloma
Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Por full text of Clinical Trial
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)
A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leuk..
A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractor...
A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 Followed by Consolidation with Anti PD1... A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Young Adult Patients ... CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CAR T-Cell Therapy
Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial.
Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios.
Comentarios
Publicar un comentario